secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001213900-26-052036
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds Pharmaceuticals appoints Sungjoon Chae as Co-CEO
--------------------------------------------------------

- Sungjoon Chae appointed Co-CEO effective May 4, 2026, pursuant to a stockholder nomination.
- No family relationships or related party transactions with company officers or directors.
- Compensation terms for Chae have not yet been determined; will be disclosed when finalized.
- Chae holds a Master of Architecture in Urban Design from Harvard University and specializes in large-scale real estate and urban regeneration.
- Existing CEO Dr. Vin Menon continues as CEO; Chae serves as Co-CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026052036/0001213900-26-052036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026052036/ea0289213-8k_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-052036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer